Boothbay Fund Management’s Alto Neuroscience ANRO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$3.26M Buy
127,624
+21,390
+20% +$642K 0.05% 382
2026
Q2
$2.8M Sell
106,234
-33,070
-24% -$765K 0.04% 569
2026
Q1
$3.13M Hold
139,304
– – 0.04% 460
2025
Q4
$2.48M Buy
139,304
+106,832
+329% +$1.35M 0.04% 499
2025
Q3
$131K Hold
32,472
– – ﹤0.01% 1703
2025
Q2
$71.4K Sell
32,472
-23,660
-42% -$56.3K ﹤0.01% 1329
2025
Q1
$121K Sell
56,132
-46,968
-46% -$168K ﹤0.01% 1217
2024
Q4
$436K Buy
+103,100
New +$643K 0.01% 929

Other funds holding ANRO

Boothbay Fund Management's ANRO Position: Q3 2026 in Review

Boothbay Fund Management increased its Alto Neuroscience (ANRO) stake by 20% in Q3 2026, buying an estimated $642K and bringing the position to 127,624 shares worth $3.26M. The position accounts for 0.05% of the portfolio, ranked #382.

Boothbay Fund Management first reported a position in ANRO in Q4 2024 and has held it in 8 quarters since. 131 funds tracked by Wall St. Rank hold ANRO as of Q3 2026.

  • Boothbay Fund Management held 127,624 shares of Alto Neuroscience worth $3.26M as of Q3 2026.
  • Boothbay Fund Management bought 21,390 Alto Neuroscience shares in Q3 2026, an estimated $642K.
  • Alto Neuroscience made up 0.05% of Boothbay Fund Management's portfolio in Q3 2026, its #382 holding.
  • Boothbay Fund Management first reported a position in Alto Neuroscience in Q4 2024 and has held it in 8 quarters since.
  • 131 funds tracked by Wall St. Rank held Alto Neuroscience as of Q3 2026.

Based on Boothbay Fund Management's 13F filing for Q3 2026, filed 16 Nov 2026.